Mr. Bradbury has been our Chief Executive Officer since March 2007, serving as President since June 2006 and as Chief Operating Officer since June 2003. He has served as a director since June 2006. He previously served as Executive Vice President from June 2000 until his promotion in June 2003. He joined Amylin in 1994 and has held officer-level positions in Corporate Development and Marketing during that time. Prior to joining Amylin, Mr. Bradbury spent ten years at SmithKline Beecham Pharmaceuticals, where he held a number of sales and marketing positions. He is a member of the board of directors of Illumina, Inc. and Novacea, Inc. He also serves as a board member for PhRMA, BIOCOM, the Keck Graduate Institute’s Board of Trustees and the San Diego Regional Economic Development Corporation. Mr. Bradbury is a member of the Royal Pharmaceutical Society of Great Britain and serves on the UCSD Rady School of Management’s Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education.

Dr. Baron has served as our Senior Vice President, Research since September 2004, and previously served as Senior Vice President, Clinical Research since June 2002. He previously served as Vice President, Clinical Research since December 1999. Dr. Baron has been clinical Professor of Medicine at the University of California, San Diego, and Clinical VA Staff Physician at the VA Medical Center, San Diego, since 2001. From 1989 to 2000, Dr. Baron worked for the Indiana University School of Medicine, where he served as Professor of Medicine and Director, Division of Endocrinology and Metabolism. Earlier, Dr. Baron held academic and clinical positions in the Division of Endocrinology and Metabolism at the University of California, San Diego, and the Veterans Administration Medical Center in San Diego. He is the recipient of several prestigious awards for his research in diabetes and vascular disease, including the 1996 Outstanding Clinical Investigator Award from the American Federation for Medical Research, several awards from the American Diabetes Association, and is a current National Institutes of Health MERIT award recipient. He earned his M.D. from the Medical College of Georgia, Augusta, and completed postdoctoral studies at the University of California, San Diego.

Mr. Foletta has served as Senior Vice President, Finance and Chief Financial Officer since March 2006.  He has previously served as Vice President, Finance and Chief Financial Officer since March 2000. Mr. Foletta previously served as a Principal of Triton Group Management, Inc. from 1997 to 2000. From 1986 to 1997, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd., the most recent of which was Senior Vice President, Chief Financial Officer and Corporate Secretary. From 1982 to 1986, Mr. Foletta was with Ernst & Young, most recently serving as an Audit Manager. He is a director of Anadys Pharmaceuticals, Inc. Mr. Foletta earned his B.A. in Business Economics from the University of California, Santa Barbara. He is a Certified Public Accountant and a member of the Financial Executives Institute.

Mr. Gergen has served as our Senior Vice President of Corporate Development since August 2006 having previously served as Vice President of Business Development since May 2005. Prior to joining us, Mr. Gergen was working as an independent consultant to biotech and medical technology companies focusing on strategy, financing and corporate development. From 2003 to 2005, Mr. Gergen was Executive Vice President at CardioNet, Inc. He held various positions at Advanced Tissue Sciences, Inc. from 2000 to 2003 most recently as Chief Restructuring Officer and Acting CEO having previously served as Senior Vice President, Chief Financial and Development Officer and Vice President, Corporate Development, General Counsel and Secretary. From 1999 to 2000, Mr. Gergen was at Premier, Inc. and from 1994 to 1999 he held various positions with Medtronic, Inc. He held positions at Jostens, Inc. in corporate development and legal from 1990 to 1994. From 1986 to 1990 he held positions with several private law firms. Mr. Gergen serves on the Board of Directors of Aperio Technologies, Inc. a private venture-backed company. Mr. Gergen received his B.A. in Business Administration from Minot State University and his J.D. from the University of Minnesota Law School.

Dr. Kolterman, one of our executive officers, has served as Senior Vice President, Development since March 2008, Senior Vice President, Clinical Affairs since February 1997 and as Senior Vice President, Regulatory Affairs since August 2005. Dr. Kolterman previously served as Vice President, Medical Affairs from July 1993 to February 1997 and Director, Medical Affairs from May 1992 to July 1993. From 1983 to May 1992, he was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center, at the University of California, San Diego Medical Center. Since 1989, he has been Adjunct Professor of Medicine at UCSD. From 1978 to 1983, he was Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver. He was a member of the Diabetes Control and Complications Trial Study Group and presently serves as a member of the Epidemiology of Diabetes Intervention and Complications Study. Dr. Kolterman also serves as a board member for Glysens, Inc., Novocell, and the ADA Research Foundation and is a past-president of the California Affiliate of the American Diabetes Association. Dr. Kolterman earned his M.D. from Stanford University School of Medicine.

Ms. Lloyd, one of our executive officers, has served as our Senior Vice President, Legal and Corporate Affairs, and General Counsel since February 2007. Prior to joining us, Ms. Lloyd served as Group Senior Vice President, Chief Administrative Officer, General Counsel and Secretary of VHA Inc. from January 2005 to February 2007. Previously, she served as VHA’s General Counsel and Secretary from May 1999 to November 2004. From 1993 to April 1999, Ms. Lloyd was Vice President and Assistant General Counsel of Medtronic, Inc. and served as Medtronic’s Assistant General Counsel from 1991 to 1993. From 1978 to 1991, Ms. Lloyd held various legal positions with Medtronic. Prior to joining Medtronic, Ms. Lloyd served as counsel to Pillsbury Company and Montgomery Ward & Co. and she taught Business Law at the University of Minnesota Business School. Ms. Lloyd is Chairperson of the Executive Leadership Foundation and an associate of the Women Business Leaders of the United States Health Care Industry Foundation. She received a B.S./B.A. from Knox College and a J.D. from Northwestern University.

Roger Marchetti
Senior Vice President, Human Resources & Information Management

Mr. Marchetti has served as our Senior Vice President, Human Resources & Information Management since July 2007, having previously served as Senior Vice President, Human Resources & Corporate Services from November 2005 to July 2007. Prior to joining us, he served as Vice President, Human Resources for Guidant Corporation from July 2002 to October 2005. Prior to this role, he served as Vice President, Finance and Information Systems, Guidant Europe, Middle East, Africa, and Canada, since the beginning of 2001. From 1999 through 2000, he served as Vice President, Human Resources for Guidant’s Vascular Intervention group, and served as Guidant’s first Corporate Controller and Chief Accounting Officer from 1994 to 1999. He joined Eli Lilly and Company’s Medical Devices and Diagnostics division in 1988. In 1992, he became Financial Manager of Lilly’s pharmaceutical manufacturing operations in Indianapolis. From 1980 to 1986, he was with the audit staff of Touche Ross & Co. (currently Deloitte). He is a Certified Public Accountant, and a graduate of LaSalle University in Philadelphia. He also received a M.B.A. from the Ross School of Business at the University of Michigan.

Joe Young
Senior Vice President, Marketing

Mr. Young has served as Senior Vice President, Marketing since October 2006.  Prior to joining Amylin, Mr. Young served as Vice President, Diabetes Brand Marketing at Novo Nordisk where he managed the full scope of marketing activities for their injectable insulin business. From 2000 until 2004, Mr. Young held various commercial leadership roles at Aventis including leading the global launch of Lantus, global New Product Planning for phase II compounds, and U.S. Brand Director for Exubera.  Mr. Young started his career at Parke-Davis where he had assignments as product manager for Rezulin, sales management, and sales.  Mr. Young received his B.S. from Texas A&M University with a concentration in pre-medicine and business.

Ms. Bauman has served as our Vice President, New Product Commercialization since November 2007.  Prior to joining Amylin, Ms. Bauman served as Senior Director of New Markets, Portfolio Expansion for Bayer Corporation after having held progressive leadership roles in Marketing and Sales for the Pharmaceutical and Biological Products Divisions at Bayer for the last 17 years. She is a Registered Dietician whose clinical training included work at Boston’s Joslin Diabetes Center. Ms. Bauman received her B.S. from the University of Vermont and holds an M.S. from Boston University as well as an R.D. from New England Deaconess Hospital in Boston.

Ms. Cadoret-Manier has been our Vice President of Brand Management since July 2007. Prior to joining us, Ms. Cadoret-Manier spent 11 years with Pfizer and brings to us 18 years of marketing, business development, and consulting experience in both national and international companies. While at Pfizer, she held progressive leadership roles in the pharmaceutical marketing arena. She worked on the launches of several major brands, including Spiriva and Viagra. She has wide therapeutic area experience including, Cardiovascular, Diabetes and Respiratory. Prior to Pfizer, Ms. Cadoret-Manier spent several years in management consulting and business development with Corning Life Sciences, Inc.

Ms. Clague has served as our Vice President and Corporate Controller since March 2008.  She previously served as Executive Director and Corporate Controller since March 2003.  Ms. Clague previously served as Controller and Director of Finance and Accounting Operations at Sony Electronics, Inc. from 1988 to 1999.   From 1985 to 1988, Ms. Clague was with Cubic Corporation as Internal Audit Supervisor.  From 1982 to 1985, Ms. Clague held various audit positions at KPMG.  Ms. Clague is a member of the board of directors of American Technology Corporation.  Ms. Clague earned her B.S. in Business Administration from Menlo College and is a Certified Public Accountant.

Dr. Crivici has served as our Vice President of Project Management & Business Process Development since March 2007, having previously served as Executive Director of Project Management & Business Process Development from September 2006 to March 2007 and Executive Director of Project Management from April 2003 to September 2006. Prior to joining us, Anna served as Global Project Leader and Director of Global Project Management at Pfizer Global Research & Development from 2001 to 2003. Anna joined Ligand Pharmaceuticals, Inc. in 1998 and served through 2001 in various Project Management roles. From 1994 to 1998 she held project management and research positions at Allelix Biopharmaceuticals, Inc. (now NPS Pharmaceuticals) and from 1981 to 1994 held research positions at Ontario Cancer Institute, Division of Structural Biology, Ontario Cancer Treatment & Research Foundation/McMaster University and Ortech (formerly Ontario Research Foundation). Dr. Crivici received her Ph.D. in Biological Chemistry from the University of Waterloo, Canada and her B.Sc. in Specialized Honor Biochemistry from the University of Guelph, Canada.

Mr. Eberhard has served as Vice President, Sales since May 2003. Prior to joining us, Mr. Eberhard was Regional Vice President, Sales, at Pharmacia Corporation, for which he had worked for 21 years. During his career with Pharmacia Corporation and its related pre-merger companies, he held positions in sales, sales management, corporate training, sales operations, and managed care before assuming the Vice President, Sales position. Mr. Eberhard received his B.S. in Biology from California Lutheran University.

Dr. Hanley has served as Vice President, Discovery Research and Chief Scientific Officer since April 2008, having previously served as Vice President, Discovery Research since October 2003. He has been a member of our Scientific Advisory Board since 1992, and previously served as a senior scientific advisor for us. Prior to joining us, Dr. Hanley held faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis, where he was Professor of Biological Chemistry. Dr. Hanley has served on advisory or review panels for the National Institutes of Health, the Medical Research Council and Wellcome Trust of Great Britain, and for the governments of Australia, Singapore, New Zealand, Hong Kong, Denmark and Japan. From 1997 to 2003, Dr. Hanley was a senior consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron Corporation. Dr. Hanley has also set-up and directed research programs in privately-held start-ups, such as Chemocentryx, PsychoGenics, and most recently Harvard-based Resolvyx Pharmaceuticals. He received his B.S. in Biochemistry and his Ph.D. in Molecular Biology from the University of California, Berkeley.

Ms. Hanssen has served as our Vice President, Commercial Operations & Strategic Relationship Management since January 2008, having previously served as Vice President, Strategic Relationship Management from March 2007 to January 2008. Prior to joining us, Ms. Hanssen spent over 11 years with Roche Diagnostics Corporation, Diabetes Care Division in Indianapolis, Indiana. While at Roche, she held a number of leadership positions for the company and most recently was their General Manager and Vice President, Disetronic Medical Systems, North America. Prior to her tenure at Roche, Ms. Hanssen worked in Marketing and New Product Development roles at TRW, Pioneer Balloon Company, Dow Chemical and Carson Pirie Scott. Ms. Hanssen served as an Executive Board Member with the Juvenile Diabetes Research Foundation International in Indianapolis and on the Fishers Indiana Chamber of Commerce Board of Directors. She also is active within Indiana University as a member of the Indiana University Women’s Colloquium, a lifetime alumni member and a Hoosier Hundred Varsity Club member. She received her M.B.A. in Marketing Management & Organizational Change and Development from Indiana University and her B.B.A. in Quantitative Management from Boise State University in Idaho.

Mr. Leonhardt has served as our Vice President and Chief Intellectual Property Counsel since September 2007. Mr. Leonhardt has over 24 years of corporate, intellectual property, litigation, executive management and mergers and acquisitions experience. Prior to joining us, Mr. Leonhardt served as Senior Vice President, General Counsel and Corporate Secretary of Senomyx, Inc. from 2003 to 2007. From 2001 to 2003 Mr. Leonhardt was Executive Vice President, General Counsel and Corporate Secretary of Genoptix, Inc. and from 1996 to 2000 he served as Vice President and then Senior Vice President, General Counsel and Corporate Secretary of Nanogen, Inc. From 1990 to 1996 Mr. Leonhardt served in various legal and management capacities at Allergan, Inc., including Assistant General Counsel, Chief Litigation Counsel and General Counsel for European Operations where he was a member of the European Management Committee. Prior to that Mr. Leonhardt was an attorney with Lyon & Lyon LLP in Los Angeles where he represented a number of prominent pharmaceutical, biotechnology and consumer products companies. He also serves as a Special Master through the California State Bar. Mr. Leonhardt received his B.Sc. degree in Pharmacy, magna cum laude, from the University of the Sciences and his J.D. from the University of Southern California School of Law.

David Maggs, MD
Vice President, Medical Affairs

Dr. Maggs has served as our Vice President, Medical Affairs since March 2005. He previously served as our Executive Director, Medical Affairs, and he joined us in October 2000 as our Senior Director, Medical Affairs. Previously, Dr. Maggs served as Director, Medical Research, Diabetes and Metabolism for Parke-Davis Co. Prior to that he was an Assistant Clinical Professor at Yale School of Medicine from 1997 to 1999 and completed fellowships at the University of Nottingham and at Yale School of Medicine. Dr. Maggs completed his original medical training at and received his M.B.B.S. and M.R.C.P. degrees from Guys Hospital, University of London and the Royal College of Physicians in London.

Paul Marshall
Vice President, Operations

Mr. Marshall has served as our Vice President, Operations since December 2006.  Prior to joining Amylin, Mr. Marshall was Vice President of Corporate Manufacturing at Amgen Inc.  From 2002 to 2005, Mr. Marshall served as Vice President of Manufacturing for Recombinant Proteins at the Bioscience Division of Baxter International, where he was responsible for five facilities with a VOS of over $1.3 Billion.  From 1999 to 2002, he was Site Head of the Baxter International Thousand Oaks facility, where he supported increased sales through expansion of the facility into a Quad-Suite and Formulation, Fill and Finishing operation.  He joined Creative BioMolecules in 1992, first as Head of Process Development and Clinical Manufacturing and then as Head of Operations, where he managed two manufacturing sites responsible for the production and commercial supply of the OP-1 implant device.  From 1988 to 1992, Mr. Marshall held various Management positions with Welgen Manufacturing Partnership (now Amgen, Rhode Island), Repligen Corporation, and Damon Biotech.  He serves as a board member for Medicago, Inc., and is a member of ISPE and ASCB.  Mr. Marshall received his M.S. and B.S. in Biology from the University of Massachusetts at Dartmouth, and performed three years of post-graduate work at Brown University in hematology and coagulation research.

Jonathan P. Mow
Vice President, Business Development

Mr. Mow has served as our Vice President, Business Development since March 2007. Prior to joining Amylin, Mr. Mow was Co-founder, Vice President, Commercial and Business Development, and Secretary of Corus Pharma, Inc. until their acquisition by Gilead Sciences in 2006.  From 1997 to 2000, Mr. Mow led the Business Development efforts for PathoGenesis Corporation, culminating with the company’s acquisition by Chiron Corporation in 2000. From 1995 to 1997, he was Associate Director, Worldwide Oncology Marketing and Strategic Business Planning at Bristol Myers-Squibb.  Earlier Mr. Mow held various positions in Marketing and Sales at Wyeth/Lederle International and Syntex Laboratories. He also serves as a board member for AerovectRx Corporation. Mr. Mow received his B.S. in Mechanical Engineering from the University of California, Berkeley and his M.B.A. from the Tepper School of Management at Carnegie Mellon University.

Lisa Porter, MD
Vice President, Clinical Development

Dr. Porter has served as Vice President, Clinical Development since September 2004. Prior to joining us, Dr. Porter served in various positions with GlaxoSmithKline Pharmaceuticals and its predecessor, SmithKline Beecham Pharmaceuticals, since 1999, most recently as Group Director, Metabolism Therapeutic Area, Clinical Development and Medical Affairs. Dr. Porter previously served as Associate Medical Director, Endo-Oncology, Zeneca Pharmaceuticals from 1997 to 1999. She received her M.D. from Duke University School of Medicine and completed a fellowship in Endocrinology and Metabolism at Brigham & Women’s Hospital / Harvard Medical School.

Philip C. Ranker
Vice President, Finance

Mr. Ranker has served as Amylin’s Vice President of Finance since January 2008. Prior to joining Amylin, Mr. Ranker served as Nastech’s Vice President of Finance from 2004 to 2007. From 2001 to 2004, he served as Director of Finance of ICOS Corporation. Mr. Ranker also served as Assistant Corporate Controller of Scholastic Corporation from 1999 to 2000 and was employed by Aventis Pharma from 1984 to 1999, during which time Mr. Ranker held positions of Accounting Supervisor, Finance Manager, Business Manager and Senior Finance Director. Mr. Ranker was employed as a Certified Public Accountant by Peat Marwick from 1981 to 1984. Mr. Ranker earned a B.S. in accounting from the University of Kansas. Mr. Ranker received his Certified Public Accountant license in 1982.

Dr. Rote has been our Vice President of Corporate Development, New Ventures since March 2008, having previously served as Executive Director, Exenatide Program Leader from 2004 to 2007 and as Senior Director of Clinical Research from 2003 to 2004. Dr. Rote was instrumental to Amylin during the launch of BYETTA and the management of the alliance with Eli Lilly and Company. Since 2007, he has served and will continue to serve as COO of Psylin Neurosciences, Inc., a virtual biotech company formed as a joint venture between Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc., and has responsibility for all operational aspects, as well as management and oversight of the Xenome Ltd. and BioSeek, Inc. collaborations. Prior to joining Amylin, Dr. Rote held various positions at Corvas International, Inc., most recently Executive Director, Biologics Development. He received his B.S. in Pre-Medicine and his Ph.D. in Pharmacology from the Pennsylvania State University.

Mr. Rowland has served as our Vice President, Governance and Compliance, and Corporate Secretary since February 2007. He previously served as our Vice President, Legal, Secretary and General Counsel from September 2001 to February 2007. Prior to joining us, Mr. Rowland served in various positions at Alliance Pharmaceutical Corp., including as Vice President beginning in 1999, Secretary beginning in 1998 and General Counsel and Assistant Secretary beginning in 1993. Earlier, Mr. Rowland served as Vice President and Senior Counsel, Finance and Securities, at Imperial Savings Association for four years. For the previous eight years, he was engaged in the private practice of corporate law with the San Diego, California law firm of Gray, Cary, Ames & Fry, and the Houston, Texas law firm of Bracewell & Patterson. He received a J.D. from Emory University.

Dr. Stetsko was appointed Vice President, Strategy and Technology Planning in September 2006. Dr. Stetsko previously served as Vice President, Operations from September 2004 to September 2006, as Vice President, Product Development from July 2002 to September 2004, and as Executive Director of Preclinical and Product Development from September 2000 to July 2002. Prior to joining us, from 1999 to 2000 he was an independent consultant providing regulatory, quality assurance and product development support to biotech companies. From 1994 to 1999, Dr. Stetsko was responsible for product development at Ligand Pharmaceuticals, most recently as the Senior Director of Pharmaceutical and Analytical Development. From 1987 to 1994, he held a number of management positions at Sterling Winthrop, most recently Associate Director of Pharmaceutical Sciences. Prior to employment at Sterling Winthrop, from 1983 to 1987, Dr. Stetsko was a senior research scientist at Sandoz, Ltd. He received his B.S. in Pharmacy from the University of Rhode Island and his Ph.D. in Industrial and Physical Pharmacy from Purdue University.

Reed Vickerman
Vice President, Corporate Operations

Mr. Vickerman serves as Vice President, Corporate Operations (Engineering, Facilities and Site Services). He previously served as Amylin’s Vice President of Information Technology (IT) and Facilities, joining the Company in 2001. Prior to Amylin, Mr. Vickerman was Vice President of IT and Facilities at Copper Mountain Networks, Senior Director of IT at Dura Pharmaceuticals, and Director of IT at Advanced Tissue Sciences. Mr. Vickerman was a Management Consultant with PriceWaterhouse and began his career at Hewlett-Packard where he held positions in Finance and IT. Mr. Vickerman received his B.S. in Managerial Economics from Carnegie Mellon University. He serves on the biotechnology manufacturing advisory board for UCSD Extension, the UCSD Undergraduate Scholarship Council (Chancellor’s Challenge 5K co-chair), the boards of Voices for Children, MoveSD (transit advocacy), San Diego Data Processing Corporation and was a founding board member of the Life Sciences Information Technology Institute. Mr. Vickerman is a member of San Diego Social Venture Partners and is a graduate of the LEAD community leadership development program.

Dawn Viveash, MD
Vice President, Regulatory Affairs and Safety

Dawn Viveash has served as Vice President, Regulatory Affairs and Safety since November 2006. Prior to joining us, Dr. Viveash managed her own consulting business, providing clinical development, regulatory affairs and safety guidance to biopharmaceutical companies. Her experience includes all stage of development and product commercialization and she has worked with small molecules and biologics. From 2000 to 2002, she was Vice President, Regulatory Affairs, Professional Services and Safety of Immunex until its merger with Amgen at which point she became Vice President of Regulatory Affairs and Safety for Amgen. From 1995 to 1998, she was the Chief Safety Officer and Vice President for Global Pharmacovigilance for Pharmacia and The Upjohn Company in the US. She joined the pharmaceutical industry in 1986 as a drug development physician for Upjohn in the UK. Dr. Viveash received her training in Pharmacy and subsequently Medicine from London University, UK. She practiced internal medicine for a number of years and became a Member of the Royal College of Physicians.

Christian Weyer, MD, MAS-CLRE
Vice President, Clinical Research

Dr. Weyer has served as Vice President of Clinical Research since March 2008. Since joining the company in January 2001 as Director of Medical Affairs, he has held various R&D positions, most recently as Executive Director of Clinical Research. Prior to joining us, Dr. Weyer was a Visiting Scientist with the National Institutes of Health, NIDDK, in Phoenix, AZ, from 1997-2001, where he conducted clinical research on the pathophysiology of obesity and type 2 diabetes in Pima Indians. He received his MD and clinical training at the Dept. of Metabolic Disorders, WHO Collaborating Center for Diabetes Treatment and Prevention, University of Düsseldorf, Germany. Dr. Weyer also holds a postdoctoral Master’s of Advanced Studies (MAS) degree in clinical research from the University of California, San Diego, and currently serves on the program’s advisory board.